mani
plant
contain
polyhydroxyalkaloid
potent
inhibitor
glucosidas
enzym
involv
oligosaccharid
trim
import
determin
final
configur
specif
glycoprotein
human
cytomegaloviru
cmv
encod
number
glycoprotein
ultim
resid
outer
envelop
matur
virion
import
viru
infect
treatment
three
polyhydroxyalkaloid
castanospermin
cast
deoxynojirimycin
dnj
dmdp
block
growth
infecti
viru
determin
yield
reduct
plaqu
reduct
assay
howev
presenc
cast
cmv
infect
cell
continu
shed
virion
extracellular
medium
determin
electron
microscopi
envelop
glycoprotein
virion
produc
treatment
cast
mm
immunoprecipit
monoclon
antibodi
specif
gci
famili
glycoprotein
analysi
pagesd
show
absenc
gci
complex
disulphidelink
proport
increas
gci
complex
disulphidelink
result
indic
alon
link
import
cmv
infect
well
potenti
target
antivir
agent
cmv
inhibitor
glycoprotein
trim
reaction
may
defin
compon
virion
surfac
import
infect
cytomegaloviru
glycoprotein
complex
inhibitor
glycoprotein
process
enzym
castanospermin
deoxynojirimycin
introduct
number
viral
glycoprotein
rang
kda
synthes
cytomegaloviru
cmv
infect
cell
major
compon
outer
envelop
stinski
stinski
farrar
oram
envelop
glycoprotein
cmv
consid
import
viru
infect
known
induc
product
antibodi
neutralis
viru
vitro
pereira
et
al
britt
rasmussen
et
al
distinct
famili
glycoprotein
complex
express
virion
envelop
separ
ionexchang
chromatographi
kari
et
al
recent
design
gci
gcii
gclii
gci
compris
major
compon
gretch
et
al
reduc
condit
sdspage
analysi
show
gci
famili
consist
glycoprotein
kda
respect
kari
et
al
farrar
greenaway
gretch
et
al
b
one
studi
farrar
greenaway
immunoprecipit
purifi
cmv
envelop
glycoprotein
use
monoclon
antibodi
specif
kda
glycoprotein
law
et
al
reveal
three
disulphid
crossbridg
complex
kda
kda
kda
kda
kda
kda
kda
possibl
multimer
form
final
structur
oligosaccharid
constitut
nlink
glycan
attach
cmvencod
glycoprotein
depend
seri
enzym
reaction
involv
remov
addit
sugar
residu
see
fig
modif
preform
nlink
glycan
consist
nacetylglucosamin
mannos
glucos
initi
involv
remov
termin
glucos
residu
process
alphaglucosidas
activ
modif
seri
hydrolyt
transferas
reaction
furhmann
et
al
high
mannos
complex
type
oligosaccharid
fig
certain
polyhydroxyalkaloid
extract
plant
inhibitor
glucosidas
reaction
see
fig
involv
initi
trim
sugar
residu
saunier
et
al
elbein
et
al
fellow
castanospermin
cast
deoxynojirimycin
dnj
dmdp
deriv
octahydroxyindolizin
piperidin
pyrrolidin
respect
fellow
compound
found
nontox
cell
cultur
concentr
effect
reduc
glycoprotein
process
fuhrmann
et
al
tym
et
al
cmv
import
opportunist
pathogen
allograft
recipi
meyer
et
al
bett
aid
patient
tym
et
al
pose
major
threat
newborn
congenit
infect
stagno
et
al
present
studi
investig
inhibitori
effect
polyhydroxyalkaloid
cmv
growth
cell
cultur
shown
cast
dnj
dmdp
inhibit
product
infecti
viru
use
monoclon
antibodi
specif
gci
endoplasm
retk
ulum
fig
site
inhibit
polyhydroxyalkaloid
cast
dnj
dmdp
propos
sequenc
process
peptid
bound
nlink
oligosaccharid
chain
q
nacetylglucosamin
mannos
glucos
lq
galactos
sialic
acid
fucos
reaction
catalys
aglucosidas
aglucosidas
ii
amannosidas
nacetylglycosaminyl
transferas
cmannosidas
ii
nacetylglucosaminyl
transferas
ii
fucosyl
transferas
galactosyl
transferas
sialyl
transferas
complex
law
et
al
farrar
greenaway
evid
provid
inhibit
oligosaceharid
trim
glucosidas
result
product
aberr
glycoprotein
correl
loss
viru
infect
inhibitor
may
import
develop
new
antivir
strategi
cmv
human
embryo
fibroblast
hef
cell
grown
eagl
minim
essenti
medium
supplement
foetal
calf
serum
fc
mm
sodium
bicarbon
mm
hepe
buffer
mainten
medium
mm
supplement
adjust
fc
mm
sodium
bicarbon
mm
hepe
three
differ
strain
cmv
use
prototyp
strain
two
clinic
isol
strain
cmv
ir
receiv
dr
j
booth
st
georg
hospit
medic
school
cmv
isol
aid
patient
st
mari
hospit
viru
stock
prepar
store
describ
previous
tym
williamson
cast
dnj
dmdp
also
alkaloid
fagomin
fag
isol
plant
fellow
fagomin
alkaloid
relat
structur
dnj
known
inhibitor
mammalian
digest
isomaltas
schofield
et
al
action
glycoprotein
trim
enzym
investig
structur
compound
shown
fig
compound
solubl
water
appear
stabl
cultur
condit
due
restrict
suppli
compound
mm
chang
daili
supernat
fluid
harvest
detect
level
infecti
viru
pellet
virion
plaqu
reduct
assay
cultur
tray
seed
hef
cell
confluent
cell
monolay
infect
viru
give
plaqueform
unit
pfu
per
well
h
adsorpt
period
inocula
replac
ml
mm
incorpor
low
gell
temperatur
agaros
supplement
variou
concentr
test
compound
cultur
incub
fix
formalin
phosphat
buffer
salin
pb
day
infect
cell
monolay
stain
methylen
blue
remov
overlay
mean
plaqu
number
calcul
triplic
count
plot
percentag
untreat
control
log
drug
concentr
effect
dose
determin
curv
linear
regress
analysi
supernat
fluid
harvest
infect
cell
cultur
success
day
clarifi
centrffug
g
min
viru
titrat
freshli
seed
monolay
use
agaros
overlay
describ
cell
repres
cultur
x
cell
remov
treatment
pronas
pb
wash
pb
centrifug
cell
pellet
fix
h
glutaraldehyd
cacodyl
buffer
ph
sampl
wash
minimum
h
fresh
cacodyl
buffer
fix
h
osmium
tetroxid
wash
alcohol
cell
pellet
encas
agar
block
dehydr
grade
seri
alcohol
embed
araldit
use
propylen
oxid
transit
fluid
ultrathin
section
stain
alcohol
uranyl
acet
reynold
lead
citrat
prior
examin
hitachi
electron
microscop
supernat
fluid
infect
cell
cultur
eitheruntr
treat
glucosidas
inhibitor
clarifi
describ
centrifug
h
rpm
pellet
virion
pellet
resuspend
pb
either
use
immedi
store
liquid
nitrogen
resuspend
viru
method
hunter
greenwood
unincorpor
isotop
remov
centrifug
wash
pb
virion
envelop
compon
extract
immunoprecipit
describ
previous
farrar
greenaway
briefli
pellet
viru
treat
buffer
triton
solut
rain
ice
ultrason
nucleocapsid
centrifug
rpm
h
solubilis
envelop
compon
immunocomplex
use
monoclon
antibodi
law
et
al
protein
asepharos
bead
pharmacia
glycoprotein
complex
releas
protein
asepharos
bead
incub
sampl
buffer
contain
sd
tri
glycerol
bromophenol
blue
ph
rain
reduc
condit
dithiothreitol
ad
sampl
buffer
solubilis
sampl
analys
sdspage
run
gel
subsequ
dri
expos
xray
film
fuji
autoradiograph
scan
densitometr
scanner
shimadzu
describ
complex
comput
area
curv
toxic
cast
hef
cell
investig
assess
effect
cast
cell
growth
hef
cell
seed
low
number
mm
well
presenc
mm
cast
left
untreat
cell
count
six
day
growth
signific
differ
record
number
viabl
cell
presenc
absenc
cast
scarciti
compound
similar
experi
conduct
dnj
dmdp
toxic
observ
cours
experi
growth
characterist
human
cmv
hef
cell
determin
level
extracellular
viru
illustr
fig
replac
mm
daili
level
infect
repres
rate
viru
product
h
period
reflect
continu
shed
virion
extracellular
medium
consid
suitabl
model
determin
effect
treatment
glucosidas
inhibitor
hef
cell
infect
viru
multipl
infect
moi
pfucel
treat
mm
cast
left
untreat
titr
extracellular
viru
measur
begin
five
day
infect
viru
level
untreat
control
approach
maximum
treatment
either
concentr
cast
reduc
extracellular
viru
level
measur
four
day
period
fig
extracellular
viru
stock
gener
drugfre
medium
adjust
mm
cast
addit
concentr
drug
left
untreat
incub
overnight
level
viru
infect
subsequ
determin
show
similar
level
casttreat
pfuml
compar
untreat
control
pfuml
evid
cast
viricid
therefor
fail
account
reduct
viru
infect
presenc
alkaloid
effect
treatment
cast
two
relat
piperidin
dnj
fag
product
extracellular
viru
compar
use
low
passag
clinic
isol
conjunct
viru
fig
hef
cell
infect
cmv
cmr
ir
moi
pfucel
viru
moi
pfucel
treat
mm
cast
mm
dnj
mm
fag
left
untreat
extracellular
viru
monitor
least
two
success
day
describ
three
virus
treatment
cast
dnj
reduc
infect
titr
wherea
fag
form
dnj
produc
less
reduct
compar
untreat
control
abil
cast
dnj
reduc
cmv
growth
confirm
plaqu
electron
micrograph
hef
cell
infect
viru
treat
mm
cast
illustr
skeinlik
sk
structur
nuclear
inclus
associ
nucleocapsid
nc
seen
bud
nuclear
membran
x
involut
segment
cytoplasm
ic
acquir
envelop
form
matur
virion
mv
chang
fine
structur
cmv
infect
hef
cell
treat
cast
indistinguish
untreat
infect
control
cell
reduct
assay
pyrrolidin
dmdp
also
investig
antivir
activ
method
fig
viru
use
infect
cell
monolay
low
moi
pfucel
describ
materi
method
monolay
overlay
medium
contain
vari
concentr
cast
dnj
dmdp
ram
valu
determin
dose
respons
curv
similar
cast
mm
dnj
ram
lower
record
dmdp
mm
cytochem
analysi
cmvinfect
cell
treat
mm
cast
previous
reveal
cytomegal
cell
larg
intranuclear
inclus
characterist
late
stage
viru
growth
fine
structur
analysi
ultrathin
section
transmiss
electron
microscopi
em
casttreat
mm
cell
infect
viru
moi
pfucel
confirm
advanc
state
infect
see
mobberley
et
al
presenc
inhibitor
treat
untreat
infect
cell
skeinlik
inclus
numer
nucleocapsid
observ
nucleu
acquisit
viral
envelop
observ
nuclear
membran
matur
virion
found
cytoplasm
particularli
golgi
region
presenc
matur
virion
infect
cell
treat
cast
illustr
fig
virion
pellet
see
materi
method
supernat
fluid
recov
casttreat
untreat
cultur
examin
transmiss
em
neg
stain
phosphotungst
acid
gross
differ
observ
number
envelop
virion
present
either
prepar
even
though
level
infect
reduc
greater
result
shown
lower
infect
particl
ratio
clear
indic
synthesi
aberr
virion
occur
cast
treat
cell
reduc
effici
infect
order
test
differ
composit
structur
glycoprotein
express
cmv
presenc
cast
investig
made
gci
glycoprotein
complex
found
viru
envelop
recognis
monoclon
antibodi
antibodi
specif
kda
glycoprotein
common
compon
three
glycoprotein
complex
describ
introduct
confluent
hef
cell
monolay
infect
viru
moi
pfucel
treat
mm
cast
left
untreat
five
day
incub
supernat
fluid
collect
replac
fresh
mm
without
cast
virion
three
success
harvest
pool
pellet
ultracentrifug
whole
virion
subject
iodin
envelop
compon
solubilis
immunoprecipit
monoclon
analys
sdspage
nonreduc
condit
autoradiograph
imag
glycoprotein
complex
l
kda
complex
kda
complex
kda
identifi
precipit
virion
envelop
produc
drugfre
condit
virion
form
presenc
cast
characteris
absenc
comcontrol
cast
complex
fig
extracellular
viru
shed
hef
cell
infect
viru
treat
mm
cast
left
untreat
collect
three
success
day
respect
viru
suspens
pool
virion
pellet
envelop
glycoprotein
iodin
immun
precipit
radiolabel
glycoprotein
separ
sdspage
nonreduc
condit
glycoprotein
complex
kda
complex
kda
complex
kda
describ
farrar
greenaway
identifi
autoradiographi
size
determin
molecular
weight
standard
rel
amount
complex
measur
use
shimadzu
scan
densitomet
plex
fig
densitometr
scan
shown
figur
enabl
comparison
rel
amount
complex
associ
envelop
treat
untreat
virion
document
tabl
along
composit
glycoprotein
complex
conclud
complex
replac
casttreat
virion
addit
amount
complex
deduc
data
presenc
drug
kda
glycoprotein
form
confirm
sdspage
analysi
glycoprotein
precipit
reduc
condit
result
shown
absenc
envelop
compon
complex
form
correl
mark
reduct
viru
infect
tabl
associ
infect
cultur
use
fig
also
illustr
revers
natur
castinduc
chang
rais
level
viru
infect
drug
remov
inhibit
glycosyl
per
se
consid
year
viabl
strategi
antivir
chemotherapi
use
tunicamycin
dglucosamin
bhydroxynorvalin
vitro
activ
shown
influenza
viru
semliki
forest
viru
kilbourn
schwarz
klenk
schwarz
et
al
herp
simplex
viru
courtney
et
al
recent
hiv
blough
et
al
compound
affect
synthesi
glycan
precursor
clinic
efficaci
indic
use
topic
women
recurr
genit
herp
infect
blough
giuntol
glucosidas
activ
endoplasm
reticulum
involv
earli
farrar
greenaway
result
present
studi
number
parenthes
indic
molecular
weight
deglycosyl
speci
posit
inhibit
cast
monensin
indic
stage
glycoprotein
process
major
influenc
rest
pathway
gener
allow
exploit
select
antivir
target
could
possibl
quantit
differ
glycosyl
host
viru
encod
glycoprotein
natur
complex
oligosaccharid
express
virion
surfac
effect
posttransl
event
three
glucosidas
inhibitor
cast
dnj
dmdp
shown
activ
cmv
studi
along
relat
compound
methyldnj
known
inhibit
replic
mous
hepat
viru
repp
et
al
sindbi
viru
mcdowel
et
al
murin
sunkara
et
al
human
gruter
et
al
tym
et
al
walker
et
al
retrovirus
case
influenza
viru
treatment
infect
cell
inhibitor
glucosidas
activ
induc
structur
alter
major
surfac
glycoprotein
haemagglutinin
consist
retent
glucos
residu
howev
presenc
high
mannos
oligosaccharid
haemagglutinin
littl
effect
virion
assembl
subsequ
infect
burk
et
al
pan
et
al
suggest
case
sugar
composit
littl
import
interact
hostcel
receptor
present
studi
treatment
cast
affect
shed
cmv
abil
cell
make
infecti
viru
significantli
reduc
like
alkaloid
except
fag
show
littl
effect
observ
cast
account
modif
glycoprotein
express
virion
surfac
particular
appear
relat
loss
one
glycoprotein
complex
virion
envelop
effici
transport
virion
glycoprotein
precursor
surfac
cell
infect
mous
hepat
viru
depend
process
glucosidas
activ
inhibit
cast
methyldnj
result
drop
viru
yield
repp
et
al
likewis
correct
process
oligosaccharid
glycosyl
polyprotein
murin
leukaemia
viru
mulv
complex
type
essenti
transport
plasma
membran
cleavag
virion
envelop
glycoprotein
pinter
et
al
expect
cast
dnj
potent
effect
replic
mulv
sunkara
et
al
remov
glucos
residu
equal
critic
proteolyt
cleavag
sindbi
glycoprotein
precursor
effici
viru
product
modif
high
mannos
oligosaccharid
also
import
mcdowel
et
al
interest
virus
cite
hiv
gruter
et
al
resist
mannos
process
inhibitor
deoxymannojirimycin
swainsonin
cmv
loss
virion
synthes
presenc
cast
also
indic
ineffici
transport
cleavag
precursor
glycoprotein
studi
farrar
greenaway
compon
gci
famili
glycoprotein
present
virion
surfac
complex
complex
present
studi
shown
complex
complet
replac
disulphidelink
complex
absenc
see
tabl
previou
studi
monoclon
antibodi
shown
immunoprecipit
three
compon
gci
present
viru
kari
et
al
along
kda
cellassoci
glycoprotein
gretch
et
al
precursor
molecul
found
kda
glycoprotein
casttreat
cell
appear
due
retent
glucos
residu
oligosaccharid
sidechain
howev
presenc
glucosidas
inhibitor
identifi
abund
indic
compon
rang
kda
also
present
inhibit
transfer
glycoprotein
cisfac
transfac
golgi
apparatu
treatment
ionophor
monensin
complet
block
posttransl
modif
kda
precursor
gretch
et
al
exact
relationship
differ
compon
gci
fulli
defin
proteas
map
demonstr
close
similar
although
relationship
uncertain
common
precursor
gci
compon
seem
like
gretch
et
al
one
explan
result
present
studi
consist
work
gretch
colleagu
present
fig
scheme
propos
altern
pathway
fate
kda
precursor
influenc
retent
termin
glucos
residu
oligosaccharid
sidechain
presenc
cast
neither
high
mannos
intermedi
kda
gretch
et
al
propos
matur
form
fig
gener
henc
inabl
form
complex
contrast
complex
present
even
treatment
cast
fig
appear
gener
kda
precursor
identifi
gretch
et
al
would
mean
oligosaccharid
retain
high
mannos
form
may
contribut
reduc
infect
level
although
complex
oligosaccharid
may
requir
infect
process
demonstr
influenza
viru
burk
et
al
pan
et
al
even
though
natur
remain
fulli
characteris
associ
infect
presenc
cmv
surfac
compon
major
interest
studi
consid
effect
glucosidas
inhibitor
compon
gcli
gciii
gretch
et
al
need
establish
three
famili
appear
provid
epitop
import
viru
neutralis
britt
rasmussen
et
al
rasmussen
et
al
kari
et
al
observ
present
studi
could
import
implic
search
therapeut
cmv
although
yet
fulli
determin
glucosidas
inhibitor
well
toler
anim
saul
et
al
man
schnack
et
al
joubert
et
al
interest
potenti
antivir
agent
also
identif
characteris
specif
glycoprotein
complex
associ
infect
could
provid
basi
subunit
vaccin
